Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy

Table 3 Introperative and postoperative outcomes of three groups

Variables	siTP group (n = 13)	seTP group (n = 17)	PVE-only group (n = 21)	P value
Patients with major hepatectomy, n (%)	13 (100)	14 (82)	14 (67)	0.057
Surgical approach, n (%)				0.868
Right hemihepatectomy	9 (69)	12 (71)	9 (43)
Right hepatic trisegmentectomy	2 (15)	1 (6)	3 (14)
Left hemihepatectomy	1 (8)	0	1 (5)
Left hepatic trisegmentectomy	1 (8)	1 (6)	1 (5)
Operation time (min)	261.4 ± 51.8	210.7 ± 53.7	246.1 ± 66.4	0.080
Intraoperative blood loss (mL)	285.0 ± 138.7	265.7 ± 153.6	343.9 ± 136.7	0.266
Transfusion, n (%)	4 (31)	4 (29)	2 (10)	0.550
Hospital stay after surgery (d)	10.9 ± 2.1	11.9 ± 3.9	12.3 ± 3.4	0.503
Complications, n (%)				0.842
Liver failure	1 (8)	0	2 (10)
Bilirary fistula	3 (23)	4 (24)	2 (10)
Hydroperitonium	1 (8)	2 (12)	0
Hydrothorax	2 (15)	1 (6)	1 (5)
Abdominal infection	2 (15)	1 (6)	1 (5)
Perioperative death, n (%)	0	0	1 (5)	0.372
Pathologic response, n (%)				< 0.001
MPR (RT < 10%)	6 (46)	2 (12)	0
PPR (RT from 10% to 50%)	3 (23)	2 (12)	0

MPR: Major pathological response; RT: Residual tumor cells; PPR: Partial pathological response; TACE: Transarterial chemoembolization; PVE: Portal vein embolization; seTP: Sequential TACE + PVE; siTP: Simultaneous TACE + PVE.